Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Sutton, Parnetta ^a   Borgia, Jeffrey A ^a   Bonomi, Philip ^a   Plate, Janet M D ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cbp PAG; Epidermal growth factor receptors; Lung adenocarcinoma cells; Lyn; Membrane associated protein complexes lipid rafts; RACK1; Src family kinases

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE LYN; RECEPTOR FOR ACTIVATED C KINASE 1; SCAFFOLD PROTEIN; SMALL INTERFERING RNA;

ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL VIABILITY; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LUNG ADENOCARCINOMA; MEMBRANE; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL MEMBRANE; CELL SURVIVAL; ENZYME ACTIVATION; HUMANS; LUNG NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84880123280     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-76     Document Type: Article

References (77)

1. Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21(20):3798-3807. 10.1200/JCO.2003.11.069, 12953099.
2. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003, 284(1):99-110. 10.1016/S0014-4827(02)00099-X, 12648469.
3. Kanematsu T, Yano S, Uehara H, Bando Y, Sone S. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res 2003, 13(5):289-298.
4. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta 2006, 1766(1):120-139.
5. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Med Cell Biol 2001, 2(2):127-137.
6. Polosa R, Prosperini G, Leir SH, Holgate ST, Lackie PM, Davies DE. Expression of c-erbB receptors and ligands in human bronchial mucosa. Am J Respir Cell Mol Biol 1999, 20(5):914-923. 10.1165/ajrcmb.20.5.3308, 10226061.
7. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003, 21(12):2237-2246. 10.1200/JCO.2003.10.038, 12748244.
8. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Am Med Assoc 2003, 290(16):2149-2158.
9. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22(16):3238-3247. 10.1200/JCO.2004.11.057, 15310767.
10. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Sci 2004, 305(5687):1163-1167.
11. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(2):123-132. 10.1056/NEJMoa050753, 16014882.
12. Bunn PA, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR, Baron A, Zeng C, Chan DC. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 2001, 7(10):3239-3250.
13. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990, 265(14):7709-7712.
14. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003, 284(1):31-53. 10.1016/S0014-4827(02)00098-8, 12648464.
15. Holbrook MR, O'Donnell JB, Slakey LL, Gross DJ. Epidermal growth factor receptor internalization rate is regulated by negative charges near the SH2 binding site Tyr992. Biochem 1999, 38(29):9348-9356.
16. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005, 23(11):2493-2501. 10.1200/JCO.2005.01.388, 15710947.
17. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23(11):2513-2520. 10.1200/JCO.2005.00.992, 15738541.
18. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Sci 2004, 304(5676):1497-1500.
19. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sciences USA 2004, 101(36):13306-13311.
20. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2(3):e73. 10.1371/journal.pmed.0020073, 549606, 15737014.
21. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23(28):6829-6837. 10.1200/JCO.2005.01.0793, 15998907.
22. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008, 14(10):2895-2899. 10.1158/1078-0432.CCR-07-2248, 18483355.
23. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Sci (New York, NY) 2007, 316(5827):1039-1043.
24. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006, 12(13):4103-4111. 10.1158/1078-0432.CCR-05-2404, 16818711.
25. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352(8):786-792. 10.1056/NEJMoa044238, 15728811.
26. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007, 13(10):2890-2896. 10.1158/1078-0432.CCR-06-3043, 17504988.
27. Suda K, Onozato R, Yatabe Y, Mitsudomi T. EGFR T790M mutation: a double role in lung cancer cell survival?. J Thorac Oncol 2009, 4(1):1-4. 10.1097/JTO.0b013e3181913c9f, 19096299.
28. Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 2006, 12(23):7117-7125. 10.1158/1078-0432.CCR-06-0760, 17145836.
29. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. JBiolChem 1999, 274(12):8335-8343.
30. Sato K, Sato A, Aoto M, Fukami Y. c-Src phosphorylates epidermal growth factor receptor on tyrosine 845. Biochem Biophys Res Commun 1995, 215(3):1078-1087. 10.1006/bbrc.1995.2574, 7488034.
31. McCole DF, Keely SJ, Coffey RJ, Barrett KE. Transactivation of the epidermal growth factor receptor in colonic epithelial cells by carbachol requires extracellular release of transforming growth factor-alpha. J Biol Chem 2002, 277(45):42603-42612. 10.1074/jbc.M206487200, 12202486.
32. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nat 1999, 402(6764):884-888.
33. Roudabush FL, Pierce KL, Maudsley S, Khan KD, Luttrell LM. Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J Biol Chem 2000, 275(29):22583-22589. 10.1074/jbc.M002915200, 10807918.
34. Hynes NE, Schlange T. Targeting ADAMS and ERBBs in lung cancer. Cancer Cell 2006, 10(1):7-11. 10.1016/j.ccr.2006.06.012, 16843261.
35. Forsyth CB, Banan A, Farhadi A, Fields JZ, Tang Y, Shaikh M, Zhang LJ, Engen PA, Keshavarzian A. Regulation of oxidant-induced intestinal permeability by metalloprotease-dependent epidermal growth factor receptor signaling. J Pharmacol Exp Ther 2007, 321(1):84-97. 10.1124/jpet.106.113019, 17220428.
36. Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, Ma L, Wistuba II, Johnson FM, Kurie JM. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 2007, 170(1):366-376. 10.2353/ajpath.2007.060706, 1762707, 17200208.
37. Roskoski RJ. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 2005, 331(1):1-14. 10.1016/j.bbrc.2005.03.012, 15845350.
38. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006, 10(1):39-50. 10.1016/j.ccr.2006.05.024, 16843264.
39. Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, Parsons SJ. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 2001, 20(12):1465-1475. 10.1038/sj.onc.1204205, 11313890.
40. Ishizawar RC, Miyake T, Parsons SJ. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene 2007, 26(24):3503-3510. 10.1038/sj.onc.1210138, 17173075.
41. Scapini P, Pereira S, Zhang H, Lowell CA. Multiple roles of Lyn kinase in myeloid cell signaling and function. Immunol Rev 2009, 228(1):23-40. 10.1111/j.1600-065X.2008.00758.x, 3248569, 19290919.
42. Hibbs ML, Dunn AR. Lyn, a src-like tyrosine kinase. Int J Biochem Cell Biol 1997, 29(3):397-400. 10.1016/S1357-2725(96)00104-5, 9202419.
43. Zucchi I, Prinetti A, Scotti M, Valsecchi V, Valaperta R, Mento E, Reinbold R, Vezzoni P, Sonnino S, Albertini A, et al. Association of rat8 with Fyn protein kinase via lipid rafts is required for rat mammary cell differentiation in vitro. ProcNatlAcadSciUSA 2004, 101(7):1880-1885.
44. Siyanova EY, Serfas MS, Mazo IA, Tyner AL. Tyrosine kinase gene expression in the mouse small intestine. Oncogene 1994, 9(7):2053-2057.
45. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim S-J, Wang Z, Gallick GE. Targeting Src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008, 68(9):3323-3333. 10.1158/0008-5472.CAN-07-2997, 18451159.
46. Lepanto P, Bryant DM, Rossello J, Datta A, Mostov KE, Kierbel A. Pseudomonas aeruginosa interacts with epithelial cells rapidly forming aggregates that are internalized by a Lyn-dependent mechanism. Cell Microbiol 2011, 13(8):1212-1222. 10.1111/j.1462-5822.2011.01611.x, 21615664.
47. Kannan S, Audet A, Knittel J, Mullegama S, Gao GF, Wu M. Src kinase Lyn is crucial for Pseudomonas aeruginosa internalization into lung cells. Eur J Immunol 2006, 36(7):1739-1752. 10.1002/eji.200635973, 16791881.
48. Kannan S, Audet A, Huang H, Chen L-J, Wu M. Cholesterol-rich membrane rafts and Lyn are involved in phagocytosis during pseudomonas aeruginosa infection. J Immunol 2008, 180(4):2396-2408.
49. Hibbs ML, Harder KW, Armes J, Kountouri N, Quilici C, Casagranda F, Dunn AR, Tarlinton DM. Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J Exp Med 2002, 196(12):1593-1604. 10.1084/jem.20020515, 2196073, 12486102.
50. Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R, Stacker SA, Dunn AR. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995, 83(2):301-311. 10.1016/0092-8674(95)90171-X, 7585947.
51. Xu Y, Harder KW, Huntington ND, Hibbs ML, Tarlinton DM. Lyn tyrosine kinase: accentuating the positive and the negative. Immun 2005, 22(1):9-18.
52. Wheeler SE, Morariu EM, Bednash JS, Otte CG, Seethala RR, Chiosea SI, Grandis JR. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Clin Cancer Res 2012, 18(10):2850-2860. 10.1158/1078-0432.CCR-11-2486, 3433855, 22490227.
53. Chan CM, Jing S, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR, Schweppe RE. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res 2012, 18(13):3580-3591. 10.1158/1078-0432.CCR-11-3359, 22586301.
54. Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M, Eschrich S, Altiok S, Koomen J, Haura EB. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 2012, 72(10):2501-2511. 10.1158/0008-5472.CAN-11-3015, 22461510.
55. Su N, Peng L, Xia B, Zhao Y, Xu A, Wang J, Wang Y, Jiang B. Lyn is involved in CD24-induced ERK1/2 activation in colorectal cancer. Mol Cancer 2012, 11:43. 10.1186/1476-4598-11-43, 3464950, 22731636.
56. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci 2005, 102(10):3788-3793. 10.1073/pnas.0409773102, 553328, 15731348.
57. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000, 275(12):8806-8811. 10.1074/jbc.275.12.8806, 10722725.
58. Yamamoto N, Mammadova G, Song RX-D, Fukami Y, Sato K-I, Yamamoto N, Mammadova G, Song RX-D, Fukami Y, Sato K-I. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells. J Cell Sci 2006, 119(22):4623-4633. 10.1242/jcs.03236, 17062641.
59. Ron D, Chen CH, Caldwell J, Jamieson L, Orr E, Mochly-Rosen D. Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins. Proc Natl Acad Sci USA 1994, 91(3):839-843. 10.1073/pnas.91.3.839, 521407, 8302854.
60. Chang BY, Chiang M, Cartwright CA. The interaction of Src and RACK1 is enhanced by activation of protein kinase C and tyrosine phosphorylation of RACK1. J Biol Chem 2001, 276(23):20346-20356. 10.1074/jbc.M101375200, 11279199.
61. Zhang W, Zong CS, Hermanto U, Lopez-Bergami P, Ronai Z, Wang LH. RACK1 recruits STAT3 specifically to insulin and insulin-like growth factor 1 receptors for activation, which is important for regulating anchorage-independent growth. Mol Cell Biol 2006, 26(2):413-424. 10.1128/MCB.26.2.413-424.2006, 1346890, 16382134.
62. Mamidipudi V, Cartwright CA. A novel pro-apoptotic function of RACK1: suppression of Src activity in the intrinsic and Akt pathways. Oncogene 2009, 28(50):4421-4433. 10.1038/onc.2009.293, 19767770.
63. Chong YP, Ia KK, Mulhern TD, Cheng HC. Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases. Biochim Biophys Acta 2005, 1754(1-2):210-220.
64. Brdicka T, Pavlistova D, Leo A, Bruyns E, Korinek V, Angelisova P, Scherer J, Shevchenko A, Shevchenko A, Hilgert I, et al. Phosphoprotein Associated with Glycosphingolipid-Enriched Microdomains (Pag), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase Csk and is involved in regulation of T cell activation. The J of Exptl Med 2000, 191(9):1591-1604.
65. Oneyama C, Hikita T, Enya K, Dobenecker MW, Saito K, Nada S, Tarakhovsky A, Okada M. The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src. Mol Cell 2008, 30(4):426-436. 10.1016/j.molcel.2008.03.026, 18498747.
66. Ingley E. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta (BBA) - Proteins & Proteomic 2008, 1784(1):56-65. 10.1016/j.bbapap.2007.08.012, 23872533.
67. Yasuda K, Nagafuku M, Shima T, Okada M, Yagi T, Yamada T, Minaki Y, Kato A, Tani-Ichi S, Hamaoka T, et al. Cutting edge: Fyn is essential for tyrosine phosphorylation of Csk-binding protein/phosphoprotein associated with glycolipid-enriched microdomains in lipid rafts in resting T cells. J Immunol 2002, 169(6):2813-2817.
68. Tauzin S, Ding H, Burdevet D, Borisch B, Hoessli DC. Membrane-associated signaling in human B-lymphoma lines. Exp Cell Res 2011, 317(2):151-162. 10.1016/j.yexcr.2010.09.011, 20875408.
69. Tauzin S, Ding H, Khatib K, Ahmad I, Burdevet D, van Echten-Deckert G, Lindquist JA, Schraven B, N-u D, Borisch B, et al. Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts. Blood 2008, 111(4):2310-2320. 10.1182/blood-2007-05-090985, 18070987.
70. Thornton C, Tang K-C, Phamluong K, Luong K, Vagts A, Nikanjam D, Yaka R, Ron D. Spatial and temporal regulation of RACK1 function and N-methyl-D-aspartate receptor activity through WD40 motif-mediated dimerization. J Biol Chem 2004, 279(30):31357-31364. 10.1074/jbc.M402316200, 15140893.
71. Cao X-X, Xu J-D, Xu J-W, Liu X-L, Cheng Y-Y, Wang W-J, Li Q-Q, Chen Q, Xu Z-D, Liu X-P. RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo. Breast Cancer Res Treat 2010, 123(2):375-386. 10.1007/s10549-009-0657-x, 19946739.
72. Nagashio R, Sato Y, Matsumoto T, Kageyama T, Satoh Y, Shinichiro R, Masuda N, Goshima N, Jiang S-X, Okayasu I. Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. Lung Cancer 2010, 69:54-59. 10.1016/j.lungcan.2009.09.015, 19892429.
73. Wang F, Osawa T, Tsuchida R, Yuasa Y, Shibuya M. Down-regulation of RACK1 suppresses tumor growth by inhibiting tumor cell proliferation and tumor-associated angiogenesis. Cancer Sci 2011, 102:2007-2013. 10.1111/j.1349-7006.2011.02065.x, 21848913.
74. Choi Y, Rho J, Jeon B-S, Choi S, Park S, Lee S, Kim H-R, Kim C, Lee J. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. Cancer Chemother Pharmacol 2010, 66(2):381-388. 10.1007/s00280-009-1174-7, 19921194.
75. Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A, Semeraro A, Del Sordo R, Tofanetti FR, Mameli MG, et al. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 2009, 20(5):842-849. 10.1093/annonc/mdn727, 19153117.
76. Pallis A, Briasoulis E, Linardou H, Papadimitriou C, Bafaloukos D, Kosmidis P, Murray S. Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations. Curr Med Chem 2011, 18(11):1613-1628. 10.2174/092986711795471383, 21428885.
77. Yang L, Li J, Ran L, Pan F, Zhao X, Ding Z, Chen Y, Peng Q, Liang H. Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells. J Gastrointest Surg 2011, 15(6):942-957. 10.1007/s11605-011-1504-z, 21479670.